编者按：当地时间4月29日，ASCO官网公布了今年5月29~31日将以线上会议形式举行的ASCO 2020大会日程及摘要题目。
在消化肿瘤领域，此次大会有2项中国研究入选oral摘要演讲。本文总结ASCO 2020在线会议日程以及消化肿瘤领域摘要、重磅研究及oral报告如下。
Abstract 4506：多纳非尼对比索拉非尼作为晚期肝细胞癌一线治疗：一项开放标签、随机、多中心Ⅱ/Ⅲ期临床试验
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Author(s):Feng Bi毕锋（四川大学华西医院）, Shukui Qin秦叔逵（东部战区总医院）, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen
Abstract 4507：阿帕替尼二线治疗中国晚期肝细胞癌患者：一项随机、安慰剂对照、双盲、Ⅲ期研究
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma:A randomized, placebo-controlled, double-blind, phase III study.
Author(s):Qiu Li李秋（四川大学华西医院）, Shukui Qin秦叔逵（东部战区总医院）, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan潘宏铭, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin
ASCO 2020在线会议日程
受COVID-19疫情影响，2020年美国临床肿瘤学会年会（ASCO2020）将于美国东部时间2020年5月29~31日（以下所述时间均为美国东部时间，ET）以线上会议的形式举行。读者登陆ASCO会议图书馆（meetinglibrary.asco.org），按照24个疾病类型或其他轨迹搜索250多份oral摘要演讲以及2500多份poster演讲。
▲读者可于在线日程中根据“Type”、“Track”或其他关键词进行搜索
关键日期：
4月29日11:00——公布会议日程（线上日程中包含了所有会议摘要题目）
5月13日17:00——大部分摘要将在ASCO会议图书馆公布
5月28日17:00——公布LBA摘要
5月29~31日——ASCO2020线上会议日程
会议日程计划：
5月29日当天早上8:00开始，大会将按需提供Oral，Poster Discussion和 Poster等场次报告，以及其他临床科学研讨会；会议注册者可在180天内获得数百个演讲视频和幻灯。
5月30~31日的线上会议主要为开幕式（Opening Session）、重点会议（Highlights Sessions）、临床科学专题研讨会（Special Clinical Science Symposium）等内容。
消化肿瘤领域重磅研究及口头报告目录
LBA
LBA4——帕博利珠单抗对比化疗治疗高微卫星不稳定/错配修复缺陷转移性结直肠癌：Ⅲ期KEYNOTE-177研究
Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study
Session:Plenary Session
Author(s):Thierry Andre, Kai-Keen Shiu, et al.
Discussion of LBA4
Session:Plenary Session
Discussant:Michael J. Overman, MD| The University of Texas MD Anderson Cancer Center
胃肠道肿瘤——胃食管、胰腺、肝胆
Abstract 4500：曲妥珠单抗三联疗法治疗HER2过表达食管腺癌：NRG Oncology/RTOG 1010
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010
Author(s):Howard Safran, Kathryn A. Winter, et al.
Abstract 4501：ramucirumab联合FLOT方案对比FLOT方案围手术期治疗可切除食管胃腺癌(RAMSES/FLOT7)：德国AIO和意大利GOIM多中心随机Ⅱ/Ⅲ期试验的Ⅱ期部分结果
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
Author(s):Salah-Eddin Al-Batran, Ralf D. Hofheinz, et al.
Abstract 4502：曲妥珠单抗+帕妥珠单抗+FLOT方案对比FLOT方案围手术期治疗HER2阳性可切除食管胃腺癌患者：PETRARCA-AIO Ⅱ期研究最终结果
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
Author(s):Ralf D. Hofheinz, Georg Martin Haag, et al.
Abstract 4503：帕博利珠单抗对比紫杉醇治疗既往治疗过的PD-L1阳性晚期胃或胃食管交界部癌(GC)患者：Ⅲ期KEYNOTE-061试验的更新
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
Author(s):Charles S. Fuchs, Mustafa zgürolu, et al.
Abstract 4504：SWOG S1505：围手术期化疗（peri-op CTx）+ mFOLFIRINOX对比吉西他滨/白蛋白结合紫杉醇（Gem/nabP）治疗可切除胰腺导管腺癌的结果
SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).
Author(s):Davendra Sohal, Mai T. Duong, et al.
Abstract 4505：ESPAC-5F：即刻手术对比新辅助吉西他滨+卡培他滨或FOLFIRINOX或化放疗（CRT）治疗交界性可切除胰腺癌患者的4臂、前瞻性、多中心、国际随机Ⅱ期试验
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
Author(s):Paula Ghaneh, Daniel H. Palmer, et al.
Abstract 4506：多纳非尼对比索拉非尼作为晚期肝细胞癌一线治疗：一项开放标签、随机、多中心Ⅱ/Ⅲ期临床试验
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Author(s):Feng Bi毕锋（四川大学华西医院）, Shukui Qin秦叔逵（东部战区总医院）, et al.
Abstract 4507：阿帕替尼二线治疗中国晚期肝细胞癌患者：一项随机、安慰剂对照、双盲、Ⅲ期研究
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma:A randomized, placebo-controlled, double-blind, phase III study.
Author(s):Qiu Li李秋（四川大学华西医院）, Shukui Qin秦叔逵（东部战区总医院）, et al.
Abstract 4508：一种新药tremelimumab联合度伐单抗治疗晚期肝细胞癌的疗效、耐受性和生物学活性
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
Author(s):Robin K. Kelley, Bruno Sangro, et al.
胃肠道肿瘤——结直肠和肛门
Abstract 4000：曲妥珠单抗-deruxtecan(T-DXd; DS-8201)治疗HER2表达的转移性结直肠癌(mCRC)的Ⅱ期、多中心、开放标签研究：DESTINY-CRC01
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Author(s):Salvatore Siena, Maria Di Bartolomeo, et al.
Abstract 4001：随机、3臂、Ⅲ期研究BEACON CRC最新生存期结果：Encorafenib联合西妥昔单抗±binimetinib对比研究者选择的伊立替康+西妥昔单抗（对照）或FOLFIRI+西妥昔单抗（对照）治疗BRAF V600E转移性结直肠癌
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Author(s):Scott Kopetz, Axel Grothey, et al.
Abstract 4002：FOLFOX+帕尼单抗对比5FU+帕尼单抗一线治疗RAS-BRAF野生型转移性结直肠癌早期患者：PANDA研究
First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.
Author(s):Sara Lonardi, Marta Schirripa, et al.
Abstract 4003：塞来昔布在5-FU、白细胞介素、奥沙利铂（FOLFOX）的标准辅助治疗Ⅲ期结肠癌中的作用：来自CALGB/SWOG 80702研究的结果
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.
Author(s):Jeffrey A. Meyerhardt, Qian Shi, et al.
Abstract 4004：Ⅲ期结肠癌患者奥沙利铂和以氟嘧啶为基础的辅助治疗3个月对比治疗6个月的OS和长期DFS：IDEA最终结果
Overall survival (OS) and long-term disease-free survival (DFS) of three versussix months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
Author(s):Alberto F. Sobrero, Thierry Andre, et al.
Abstract 4005：比较肝切除术后mFOLFOX6与单纯肝切除术治疗结直肠癌肝转移的疗效：一项随机Ⅱ/Ⅲ期试验
A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study.
Author(s):Yukihide Kanemitsu, Yasuhiro Shimizu, et al.
Abstract 4006：局部进展期直肠癌TME前短程放疗后化疗：RAPIDO随机试验
Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.
Author(s):Geke Hospers, Renu R. Bahadoer, et al.
Abstract 4007：局部进展期直肠癌患者mFOLFIRINOX对比术前同步放化疗进行全程新辅助治疗：UNICANCER GI试验PRODIGE 23 III期试验的最终结果
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
Author(s):Thierry Conroy, Najib Lamfichekh, et al.
Abstract 4008：直肠腺癌(OPRA)器官保留试验的初步结果
Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.
Author(s):Julio Garcia-Aguilar, Sujata Patil, et al.
閱讀更多 雲醫會 的文章
